It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Malaria is a causative factor in about 500.000 deaths each year world-wide. Cerebral malaria is a particularly severe complication of this disease and thus associated with an exceedingly high mortality. Malaria retinopathy is an ocular manifestation often associated with cerebral malaria, and presumably shares a substantial part of its pathophysiology. Here, we describe that indeed murine malaria retinopathy reproduced the main hallmarks of the corresponding human disease. In the living animal, we were able to follow the circulation and cellular localization of malaria parasites transgenically labelled with GFP via non-invasive in vivo retinal imaging. We found that malaria parasites cross the blood-retinal-barrier and infiltrate the neuroretina, concomitant with an extensive, irreversible, and long-lasting retinal neurodegeneration. Furthermore, anti-malarial treatment with dihydroartemisinin strongly diminished the load of circulating parasites but resolved the symptoms of the retinopathy only in part. In summary, we introduce here a novel preclinical model for human cerebral malaria that is much more directly accessible for studies into disease pathophysiology and development of novel treatment approaches. In vivo retinal imaging may furthermore serve as a valuable tool for the early diagnosis of the human disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Tübingen, Cell Death Mechanisms Lab, Institute for Ophthalmic Research, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
2 University of Tübingen, Division of Ocular Neurodegeneration, Institute for Ophthalmic Research, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
3 University of Tübingen, Institute for Ophthalmic Research, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tübingen, Centre for Integrative Neuroscience (CIN), Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
4 University of Tübingen, Institute for Ophthalmic Research, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
5 University of Tübingen, Institute of Tropical Medicine, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)
6 Institute for Ophthalmic Research, University of Tübingen, Experimental Vitreoretinal Surgery, Tübingen, Germany (GRID:grid.10392.39)